The sponsor reviewed the manuscript before it was submitted for publication but didn't control the interpretation of the results or the decision to submit the manuscript for publication. The scholarly study was designed by the look committee and executive committee, the participating investigators collected the data, and all of the authors wrote the manuscript. The executive committee made a decision to post the manuscript for publication. The coordinating center had full usage of the data and vouches for the accuracy and completeness of the info and analysis. The executive committee and the coordinating center vouch for the fidelity of the study to the protocol. Merck donated losartan and lisinopril for the analysis but was not mixed up in study design, data analysis, or manuscript preparation.The pharmaceutical organization could obtain a reassessment of vandetanib within a changeover period and post a fresh dossier to the Government Joint Committee . Best supportive treatment as the appropriate comparator therapy In the newly submitted dossier, the company now presented an analysis of data for sufferers who were treated according to the approval status. As specified by the G-BA, vandetanib was compared with best supportive care . This means the best possible supportive therapy, optimized for the individual individual for alleviation of symptoms and improvement in the quality of life.